会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 38. 发明授权
    • Aminopyrazole derivatives
    • 氨基吡唑衍生物
    • US6166038A
    • 2000-12-26
    • US319270
    • 1999-07-30
    • Takehiro FukamiTakahiro FukurodaAkio KanataniMasaki Ihara
    • Takehiro FukamiTakahiro FukurodaAkio KanataniMasaki Ihara
    • C07D231/40C07D401/12A61K31/445A61K31/415C07D231/38
    • C07D401/12C07D231/40
    • The present invention relates to a compound represented by the general formula [I]: ##STR1## wherein Ar.sup.1 represents an aryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl and lower haloalkyl groups; Ar.sup.2 represents an aryl or heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino and aryl groups; R.sup.1 and R.sup.2 may be the same or different and each represents a hydrogen atom or a lower alkyl group; R.sup.3 and R.sup.4 may be the same or different and each represents a hydrogen atom or a lower alkyl group, or R.sup.3 and R.sup.4 are linked to each other to form an alkylene group containing 2 to 4 carbon atoms which may have a lower alkyl group; and R.sup.5 represents a hydrogen atom or a lower alkyl or lower alkoxy group,or its salt, a method for its preparation as well as an agent for the treatment of bulimia, obesity or diabetes comprising it as an active ingredient.
    • PCT No.PCT / JP97 / 04571 Sec。 371日期1999年7月30日第 102(e)1999年7月30日PCT 1997年12月12日PCT PCT。 公开号WO98 / 25908 日期:1998年6月18日本发明涉及由通式[I]表示的化合物:其中Ar1表示可具有选自卤素原子和低级烷基和低级卤代烷基的取代基的芳基; Ar2表示可以具有选自卤素原子和低级烷基,低级烯基,低级卤代烷基,低级烷氧基,低级烷硫基,低级烷基氨基,低级二烷基氨基和芳基的取代基的芳基或杂芳基; R 1和R 2可以相同或不同,各自表示氢原子或低级烷基; R 3和R 4可以相同或不同,各自表示氢原子或低级烷基,或者R 3和R 4相互连接形成可以具有低级烷基的含有2〜4个碳原子的亚烷基; R5代表氢原子或低级烷基或低级烷氧基,或其盐,其制备方法以及用于治疗贪食症,肥胖症或糖尿病的药物,其包含其作为活性成分。
    • 39. 发明授权
    • Pyrazole derivatives
    • 吡唑衍生物
    • US06057335A
    • 2000-05-02
    • US319260
    • 1999-07-30
    • Takehiro FukamiTakahiro FukurodaAkio KanataniMasaki Ihara
    • Takehiro FukamiTakahiro FukurodaAkio KanataniMasaki Ihara
    • C07D231/40C07D401/04C07D401/12C07D403/04C07D403/12C07D405/04C07D405/12C07D409/12C07D487/04A61K31/473A61K31/4155A61K31/4439C07D401/14
    • C07D401/04C07D231/40C07D401/12C07D403/04C07D403/12C07D405/04C07D405/12C07D409/12C07D487/04
    • The present invention relates to a compound represented by the general formula [I]: ##STR1## wherein A and B rings are ortho-condensed to each other, A ring represents an aromatic carbocyclic or heterocyclic ring and B ring represents an aliphatic four- to seven-membered carbocyclic or nitrogen-containing heterocyclic ring, said nitrogen atom being possible to present at only the position where the A ring is condensed; Ar represents an aromatic carbocyclic or heterocyclic ring group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino and aromatic carbocyclic ring groups; and R represents a substituent selected from the group consisting of a halogen atom and nitro, lower alkyl, lower alkoxy, aromatic carbocyclic ring groups and a carbonyl group having an aromatic carbocyclic ring group, or a hydrogen atom, provided that when the group represented by ##STR2## is the group represented by ##STR3## Ar is not a phenyl group nor a 4-chlorophenyl group, or its salt, a method for its preparation as well as an agent for the treatment of bulimia, obesity or diabetes comprising it as an active ingredient.
    • 本发明涉及由通式[I]表示的化合物:其中A和B环彼此原子稠合,A环表示芳族碳环或杂环,B环表示脂族四至七元 碳环或含氮杂环,所述氮原子只能存在于A环稠合的位置; Ar表示可以具有选自卤素原子和低级烷基,低级烯基,低级卤代烷基,低级烷氧基,低级烷硫基,低级烷基氨基,低级二烷基氨基和芳族碳环基团的取代基的芳族碳环或杂环基团; R表示选自卤素原子和硝基,低级烷基,低级烷氧基,芳香族碳环基团和具有芳香族碳环基团的羰基或氢原子的取代基,条件是当以 是由Ar表示的基团不是苯基或4-氯苯基,或其盐,其制备方法以及用于治疗包含其作为活性成分的贪食症,肥胖症或糖尿病的药剂。
    • 40. 发明授权
    • Urea derivatives
    • 尿素衍生物
    • US6043246A
    • 2000-03-28
    • US308668
    • 1999-07-26
    • Takehiro FukamiTakahiro FukurodaAkio KanataniMasaki Ihara
    • Takehiro FukamiTakahiro FukurodaAkio KanataniMasaki Ihara
    • C07D231/40C07D401/04C07D401/12C07D403/12C07D405/04A61K31/415A61K31/496
    • C07D401/04C07D231/40C07D401/12C07D403/12C07D405/04
    • The present invention relates to a compound represented by the general formula [I]: ##STR1## wherein A represents a nitrogen atom or a group represented by C--R.sup.5 ; Ar.sup.1 represents an aryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl and lower haloalkyl groups; Ar.sup.2 represents an aryl or heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino and aryl groups; R.sup.1 represents a hydrogen atom, a lower alkyl group or a bond formed by linking to R.sup.5 ; R.sup.2 represents a hydrogen atom or a lower alkyl group; R.sup.3 and R.sup.4 may be the same or different and each represents a hydrogen atom or a lower alkyl group, or R.sup.3 and R.sup.4 are linked to each other to form an alkylene group containing 2 to 4 carbon atoms which may have a lower alkyl group; and R.sup.5 represents a hydrogen atom or a hydroxyl, lower alkyl or lower alkoxy group or a bond formed by linking to R.sup.1,or its salt, a process for its preparation and an agent for the treatment of bulimia, obesity or diabetes comprising it as an active ingredient.
    • PCT No.PCT / JP97 / 04399 Sec。 371日期:1999年7月26日 102(e)日期1999年7月26日PCT 1997年12月2日PCT公布。 WO98 / 24768 PCT公开号 日期:1998年6月11日本发明涉及由通式[I]表示的化合物:其中A表示氮原子或C-R5表示的基团; Ar 1表示可以具有选自卤素原子和低级烷基和低级卤代烷基的取代基的芳基; Ar2表示可以具有选自卤素原子和低级烷基,低级烯基,低级卤代烷基,低级烷氧基,低级烷硫基,低级烷基氨基,低级二烷基氨基和芳基的取代基的芳基或杂芳基; R1表示氢原子,低级烷基或通过连接到R5形成的键; R2表示氢原子或低级烷基; R 3和R 4可以相同或不同,各自表示氢原子或低级烷基,或者R 3和R 4相互连接形成可以具有低级烷基的含有2〜4个碳原子的亚烷基; R5表示氢原子或羟基,低级烷基或低级烷氧基或通过连接R1或其盐形成的键,其制备方法和用于治疗贪食,肥胖或糖尿病的药物,其包含其作为 有效成分。